人胰岛素药物和输送设备市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按药物类型(基础或长效胰岛素、丸剂或速效胰岛素、传统人胰岛素、组合胰岛素和生物仿制药胰岛素)、设备类型(胰岛素笔、胰岛素泵、胰岛素注射器和喷射注射器)细分) 和地理。

市场快照

Human Insulin Drugs and Devices Market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 0 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

在 2019-2024 年的预测期内,人胰岛素药物和输送设备市场的复合年增长率预计为 5.5%,预计到 2019 年将达到 300 亿美元以上。 

  • 糖尿病通常被认为是一种与生活方式有关的疾病。随着时间的推移,随着世界各地人口的增加,这种疾病的发病率急剧增加。
  • 全世界约有 1 亿人需要胰岛素,包括所有 1 型糖尿病患者和 10-25% 的 2 型糖尿病患者。
  • 尽管胰岛素用于治疗糖尿病已有 90 多年的历史,但在全球范围内,今天需要胰岛素的人中有一半以上仍然无法负担和获得它。1 型糖尿病患者需要胰岛素治疗,该治疗的重点是控制血糖水平以及胰岛素、饮食和生活方式,以预防并发症。

报告范围

市场按药物类型(基础或长效胰岛素、推注或速效胰岛素、传统人胰岛素、组合胰岛素和生物仿制药胰岛素)、设备类型(胰岛素笔、胰岛素泵、胰岛素注射器和喷射注射器)进行细分) 和地理。

By Drug (Value and Volume, 2012-2024)
Basal or Long Acting Insulins
Lantus (Insulin glargine)
Levemir (Insulin detemir)
Tresiba (Insulin degludec)
Toujeo (Insulin glargine)
Basaglar (Insulin glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin aspart)
Humalog (Insulin lispro)
Apidra (Insulin glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro Sanofi)
Traditional Human Insulins
Novolin/Mixtard/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins
NovoMix (Biphasic Insulin aspart)
Ryzodeg (Insulin degludec and Insulin aspart)
Xultophy (Insulin degludec and Liraglutide)
Soliqua/Suliqua (Insulin glargine and Lixisenatide)
Biosimilar Insulins
Insulin glargine biosimilars
Human insulin biosimilars
By Device (Value and Volume, 2012-2024)
Insulin Pumps
Insulin Pump Devices
Insulin Pump Reservoirs
Insulin Infusion sets
Insulin Pens
Cartridges in reusable pens
Disposable insulin pens
Insulin Syringes
Insulin Jet Injectors
Geography
North America (Value and Volume, 2012-2024)
US
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Canada
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Rest of North America
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Europe (Value and Volume, 2012-2024)
Germany
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
UK
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
France
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Russia
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Spain
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Italy
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Rest of Europe
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Asia Pacific (Value and Volume, 2012-2024)
Australia
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
India
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
China
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Japan
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Malaysia
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
South Korea
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Thailand
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Philippines
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Vietnam
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Indonesia
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Rest of the Asia Pacific
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Latin America (Value and Volume, 2012-2024)
Brazil
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Mexico
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Rest of Latin America
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Middle East & Africa (Value and Volume, 2012-2024)
Saudi Arabia
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Iran
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Egypt
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Oman
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
South Africa
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)
Rest of the Middle East Africa
By Drugs (Segment & Sub-segment)
By Devices (Segment & Sub-segment)

Report scope can be customized per your requirements. Click here.

主要市场趋势

肥胖和 2 型糖尿病患病率不断增加,尤其是在发展中国家

 

  • 1 型糖尿病的确切原因尚不清楚,但 2 型糖尿病是由日常生活方式的改变和选择引起的。与十年前相比,2 型糖尿病的患病率翻了两番。
  • 尽管口服抗糖尿病药物被认为是 2 型糖尿病患者的护理标准,但使用胰岛素和常规药物的需求有所增加,以帮助稳定血糖水平。这一趋势吸引了许多本地和国际参与者进入生物仿制药市场。
  • 在过去的二十年中,2 型糖尿病 (T2DM) 的患病率急剧增加,这一事实是由肥胖发病率增加和 T2DM 的主要危险因素驱动的。糖尿病是美国快速增长的慢性病之一。
  • 印度是糖尿病发病率最高的三个国家之一。许多报告和调查都记录了基于生活习惯的糖尿病人口急剧增加。
  • 胰岛素领域的研发正在逐年上升,因为研究人员正试图为患者提供最好的分子,抑制最大的副作用,并提高他们的效率。因此,全球肥胖和糖尿病患病率的增加可能会增加对胰岛素的需求,进而推动胰岛素设备市场。
Human Insulin Drugs and Devices Market Key trend1

北美主导市场

 

  • 由于该地区糖尿病的高发病率,北美在市场上占主导地位,尤其是美国。这在很大程度上归因于久坐不动的生活方式选择和变化,以及该地区新药的推出。
  • 成本因素是美国最关心的问题,制造商近 50% 的胰岛素收入来自该国本身。 
  • 据估计,美国将在 2018 年主导胰岛素输送设备市场,其次是中国和日本。
  • 由于肥胖率高和该地区对糖尿病护理意识的提高等因素,预计亚太市场将在预测期内大幅增长。    
Insulin drugs and Devices

竞争格局

  • 市场高度整合,三大制造商在全球市场占有一席之地,其余制造商仅限于其他本地或特定地区的制造商。
  • 最近发生在参与者之间的并购帮助这些公司加强了他们的市场占有率。礼来(Eli Lilly)和勃林格殷格翰(Boehringer Ingelheim)共同开发和商业化 Basaglar(甘精胰岛素)。
  • 此外,最近的参与者帮助公司加强了市场占有率;例如,诺和诺德与 Ypsomed 合作提供更好的胰岛素治疗解决方案。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Industry Attractiveness - Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug (Value and Volume, 2012-2024)

      1. 5.1.1 Basal or Long Acting Insulins

        1. 5.1.1.1 Lantus (Insulin glargine)

        2. 5.1.1.2 Levemir (Insulin detemir)

        3. 5.1.1.3 Tresiba (Insulin degludec)

        4. 5.1.1.4 Toujeo (Insulin glargine)

        5. 5.1.1.5 Basaglar (Insulin glargine)

      2. 5.1.2 Bolus or Fast Acting Insulins

        1. 5.1.2.1 NovoRapid/Novolog (Insulin aspart)

        2. 5.1.2.2 Humalog (Insulin lispro)

        3. 5.1.2.3 Apidra (Insulin glulisine)

        4. 5.1.2.4 FIASP (Insulin aspart)

        5. 5.1.2.5 Admelog (Insulin lispro Sanofi)

      3. 5.1.3 Traditional Human Insulins

        1. 5.1.3.1 Novolin/Mixtard/Actrapid/Insulatard

        2. 5.1.3.2 Humulin

        3. 5.1.3.3 Insuman

      4. 5.1.4 Combination Insulins

        1. 5.1.4.1 NovoMix (Biphasic Insulin aspart)

        2. 5.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)

        3. 5.1.4.3 Xultophy (Insulin degludec and Liraglutide)

        4. 5.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)

      5. 5.1.5 Biosimilar Insulins

        1. 5.1.5.1 Insulin glargine biosimilars

        2. 5.1.5.2 Human insulin biosimilars

    2. 5.2 By Device (Value and Volume, 2012-2024)

      1. 5.2.1 Insulin Pumps

        1. 5.2.1.1 Insulin Pump Devices

        2. 5.2.1.2 Insulin Pump Reservoirs

        3. 5.2.1.3 Insulin Infusion sets

      2. 5.2.2 Insulin Pens

        1. 5.2.2.1 Cartridges in reusable pens

        2. 5.2.2.2 Disposable insulin pens

      3. 5.2.3 Insulin Syringes

      4. 5.2.4 Insulin Jet Injectors

    3. 5.3 Geography

      1. 5.3.1 North America (Value and Volume, 2012-2024)

        1. 5.3.1.1 US

          1. 5.3.1.1.1 By Drugs (Segment & Sub-segment)

          2. 5.3.1.1.2 By Devices (Segment & Sub-segment)

        2. 5.3.1.2 Canada

          1. 5.3.1.2.1 By Drugs (Segment & Sub-segment)

          2. 5.3.1.2.2 By Devices (Segment & Sub-segment)

        3. 5.3.1.3 Rest of North America

          1. 5.3.1.3.1 By Drugs (Segment & Sub-segment)

          2. 5.3.1.3.2 By Devices (Segment & Sub-segment)

      2. 5.3.2 Europe (Value and Volume, 2012-2024)

        1. 5.3.2.1 Germany

          1. 5.3.2.1.1 By Drugs (Segment & Sub-segment)

          2. 5.3.2.1.2 By Devices (Segment & Sub-segment)

        2. 5.3.2.2 UK

          1. 5.3.2.2.1 By Drugs (Segment & Sub-segment)

          2. 5.3.2.2.2 By Devices (Segment & Sub-segment)

        3. 5.3.2.3 France

          1. 5.3.2.3.1 By Drugs (Segment & Sub-segment)

          2. 5.3.2.3.2 By Devices (Segment & Sub-segment)

        4. 5.3.2.4 Russia

          1. 5.3.2.4.1 By Drugs (Segment & Sub-segment)

          2. 5.3.2.4.2 By Devices (Segment & Sub-segment)

        5. 5.3.2.5 Spain

          1. 5.3.2.5.1 By Drugs (Segment & Sub-segment)

          2. 5.3.2.5.2 By Devices (Segment & Sub-segment)

        6. 5.3.2.6 Italy

          1. 5.3.2.6.1 By Drugs (Segment & Sub-segment)

          2. 5.3.2.6.2 By Devices (Segment & Sub-segment)

        7. 5.3.2.7 Rest of Europe

          1. 5.3.2.7.1 By Drugs (Segment & Sub-segment)

          2. 5.3.2.7.2 By Devices (Segment & Sub-segment)

      3. 5.3.3 Asia Pacific (Value and Volume, 2012-2024)

        1. 5.3.3.1 Australia

          1. 5.3.3.1.1 By Drugs (Segment & Sub-segment)

          2. 5.3.3.1.2 By Devices (Segment & Sub-segment)

        2. 5.3.3.2 India

          1. 5.3.3.2.1 By Drugs (Segment & Sub-segment)

          2. 5.3.3.2.2 By Devices (Segment & Sub-segment)

        3. 5.3.3.3 China

          1. 5.3.3.3.1 By Drugs (Segment & Sub-segment)

          2. 5.3.3.3.2 By Devices (Segment & Sub-segment)

        4. 5.3.3.4 Japan

          1. 5.3.3.4.1 By Drugs (Segment & Sub-segment)

          2. 5.3.3.4.2 By Devices (Segment & Sub-segment)

        5. 5.3.3.5 Malaysia

          1. 5.3.3.5.1 By Drugs (Segment & Sub-segment)

          2. 5.3.3.5.2 By Devices (Segment & Sub-segment)

        6. 5.3.3.6 South Korea

          1. 5.3.3.6.1 By Drugs (Segment & Sub-segment)

          2. 5.3.3.6.2 By Devices (Segment & Sub-segment)

        7. 5.3.3.7 Thailand

          1. 5.3.3.7.1 By Drugs (Segment & Sub-segment)

          2. 5.3.3.7.2 By Devices (Segment & Sub-segment)

        8. 5.3.3.8 Philippines

          1. 5.3.3.8.1 By Drugs (Segment & Sub-segment)

          2. 5.3.3.8.2 By Devices (Segment & Sub-segment)

        9. 5.3.3.9 Vietnam

          1. 5.3.3.9.1 By Drugs (Segment & Sub-segment)

          2. 5.3.3.9.2 By Devices (Segment & Sub-segment)

        10. 5.3.3.10 Indonesia

          1. 5.3.3.10.1 By Drugs (Segment & Sub-segment)

          2. 5.3.3.10.2 By Devices (Segment & Sub-segment)

        11. 5.3.3.11 Rest of the Asia Pacific

          1. 5.3.3.11.1 By Drugs (Segment & Sub-segment)

          2. 5.3.3.11.2 By Devices (Segment & Sub-segment)

      4. 5.3.4 Latin America (Value and Volume, 2012-2024)

        1. 5.3.4.1 Brazil

          1. 5.3.4.1.1 By Drugs (Segment & Sub-segment)

          2. 5.3.4.1.2 By Devices (Segment & Sub-segment)

        2. 5.3.4.2 Mexico

          1. 5.3.4.2.1 By Drugs (Segment & Sub-segment)

          2. 5.3.4.2.2 By Devices (Segment & Sub-segment)

        3. 5.3.4.3 Rest of Latin America

          1. 5.3.4.3.1 By Drugs (Segment & Sub-segment)

          2. 5.3.4.3.2 By Devices (Segment & Sub-segment)

      5. 5.3.5 Middle East & Africa (Value and Volume, 2012-2024)

        1. 5.3.5.1 Saudi Arabia

          1. 5.3.5.1.1 By Drugs (Segment & Sub-segment)

          2. 5.3.5.1.2 By Devices (Segment & Sub-segment)

        2. 5.3.5.2 Iran

          1. 5.3.5.2.1 By Drugs (Segment & Sub-segment)

          2. 5.3.5.2.2 By Devices (Segment & Sub-segment)

        3. 5.3.5.3 Egypt

          1. 5.3.5.3.1 By Drugs (Segment & Sub-segment)

          2. 5.3.5.3.2 By Devices (Segment & Sub-segment)

        4. 5.3.5.4 Oman

          1. 5.3.5.4.1 By Drugs (Segment & Sub-segment)

          2. 5.3.5.4.2 By Devices (Segment & Sub-segment)

        5. 5.3.5.5 South Africa

          1. 5.3.5.5.1 By Drugs (Segment & Sub-segment)

          2. 5.3.5.5.2 By Devices (Segment & Sub-segment)

        6. 5.3.5.6 Rest of the Middle East Africa

          1. 5.3.5.6.1 By Drugs (Segment & Sub-segment)

          2. 5.3.5.6.2 By Devices (Segment & Sub-segment)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 diabetes population

    2. 6.2 Type-2 diabetes population

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Novo Nordisk A/S

      2. 7.1.2 Sanofi Aventis

      3. 7.1.3 Eli Lilly

      4. 7.1.4 Biocon

      5. 7.1.5 Julphar

      6. 7.1.6 Exir

      7. 7.1.7 Medtronic

      8. 7.1.8 Insulet

      9. 7.1.9 Ypsomed

      10. 7.1.10 Becton Dickinson

    2. 7.2 Company Share Analysis

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

Each drug and device market share will be provided in every country based on the availability

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Human Insulin Drugs and Delivery Devices Market market is studied from 2018 - 2026.

The Human Insulin Drugs and Delivery Devices Market is growing at a CAGR of 0% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Novo Nordisk, Sanofi, El lilly, Medtronics, Ypsomed are the major companies operating in Human Insulin Drugs and Delivery Devices Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!